Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
Official title: Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-11361630 · Data updated 2026-11-12
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,607,793 |
| NIH project number | 4R01CA285856-03 |
| Project ID | NIH-11361630 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with SMARCA4-deficient lung adenocarcinoma or related tumor biology who could participate in translational studies or future trials.
✕Less likely to help
Patients whose tumors do not involve SMARCA4 mutations or related pathways may not benefit from this specific approach.
What this research studies
Doctors and scientists will study how SMARCA4-deficient lung cancers become more invasive and spread. They will use advanced genomic and proteomic techniques, including ATAC-seq and RNA/protein analyses, to map how this cancer pathway works. The goal is to identify targets that could be blocked to prevent metastasis and improve patient outcomes.
Why it matters
Potential benefit: If successful, the research could lead to new strategies to prevent or reduce metastasis in SMARCA4-deficient LUAD, potentially extending patient survival.
How similar studies have gone: Previous work has shown that targeting related pathways can reduce invasion and metastasis in lung cancer models, supporting this line of investigation.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Jones, David R — Sloan-Kettering Inst Can Research
- Study coordinator: Jones, David R
Related research
Other NIH-funded projects on the same topics.
-
How lung adenocarcinoma spreads and hides from the immune system
This work looks at the specific lung cancer cells that let tumors spread and survive so better ways to prevent relapse can be found.
-
Stopping the spread of lung cancer in patients with a specific gene change
This research aims to find new ways to prevent lung cancer from spreading in patients who have a particular genetic change called SMARCA4 deficiency.
-
Investigating how a specific pathway affects the spread of lung cancer lacking a key protein.
This study is looking at how a missing protein in a type of lung cancer affects its ability to spread, and it hopes to find new ways to treat patients by understanding the genetic changes involved.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.